I interpret a recent Cochrane Community Blog post as inviting me to continue criticizing the Collaboration’s conflict of interest in the evaluation of “chronic fatigue syndrome” with the intent of initiating further reflection on its practices and change.
Cochrane needs to
- Clean up conflicts of interest in its systematic reviews.
- Issue a Statement of Concern about a flawed and conflicted review of exercise for chronic fatigue syndrome.
I will leave for a future blog the argument that Cochrane needs to take immediate steps to get the misnamed “chronic fatigue syndrome” out of its Common Mental Disorders group. The colloquialism throws together highly prevalent complaints in primary care of tiredness with less common, but more serious myalgic encephalomyelitis, which is recognized by the rest of the world as a medical condition, not a mental disorder.
But I think I call attention in this blog post to enough that needs change now.
The invitation from the Cochrane Community Blog to criticize its policies
I had a great Skype conference with Dr. David Tovey, Cochrane Editor in Chief and Deputy Chief Director. I’m grateful for his reaching out and his generous giving of his time, including reading my blog posts ahead of time.
In the email setting up the conversation, Dr.Tovey stated that Cochrane has a tradition of encouraging debate and that he believes that criticism helps them to improve. That is something he is very keen to foster.
Our conversation was leisurely and wide-ranging. Dr.Tovey lived up to the expectations established in his email. He said that he was finishing up a blog post in response to issues that I and others had raised. That blog post is now available here. It leads off with:
I didn’t know Bill Silverman, so I can’t judge whether he would be “a-mouldering in his grave”. However, I recognise that James Coyne has set down a challenge to Cochrane to explain its approach to commercial and academic conflicts of interest and also to respond to criticisms made in relation to the appraisal of the much debated PACE study.
Dr. Tovey closed his blog post with:
Cochrane is not complacent. We recognise that both we and the world we inhabit are imperfect and that there is a heavy responsibility on us to ensure that our reviews are credible if they are to be used to guide decision making. This means that we need to continue to be responsive and open to criticism, just as the instigators of the Bill Silverman prize intended, in order “to acknowledge explicitly the value of criticism of The Cochrane Collaboration, with a view to helping to improve its work.”
As a member of a group of authors who received the Bill Silverman prize, I am interpreting Dr. Tovey’s statement as an invitation to improve the Cochrane collaboration by instigating and sustaining a discussion of its handling of conflicts of interest in reviews of the misnamed “chronic fatigue syndrome.”
I don’t presume that Dr. Tovey will personally respond to all of my efforts. But I will engage him and hope that my criticisms and concerns will be forwarded to appropriate deliberative bodies and receive wider discussion within the Cochrane.
For instance, I will follow up on his specific suggestion by filing a formal complaint with Funding Arbiters and Arbitration Panel concerning a review and protocol with Lillebeth Larun as first author.
A flawed and conflicted Cochrane systematic review
There are numerous issues that remain unresolved in a flawed and conflicted recent Cochrane systematic review:
Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev. 2016; CD003200.
As well as a protocol for a future review:
Larun L, Odgaard-Jensen J, Brurberg KG, Chalder T, Dybwad M, Moss-Morris RE, Sharpe M, Wallman K, Wearden A, White PD, Glasziou PP. Exercise therapy for chronic fatigue syndrome (individual patient data) (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD011040.
I’m pleased that Dr. Tovey took a stand against the PACE investigators and Queen Mary University, London. He agreed sharing patient-level data for a Cochrane Review on which they were authors should not be used as an excuse to avoid sharing data with others. .
Another issue raised by Coyne has also been raised with me in personal correspondence: namely the perceived use of Cochrane as a rationale for withholding clinical trials data at the level of individual patients from other individuals and organisations. Cochrane is a strong supporter and founding member of the AllTrials initiative and is committed to clinical trials transparency. Cochrane does not believe that sharing data with its researchers is an appropriate rationale for withholding the data from alternative researchers. Each application must be judged independently on its merits. Cochrane has issued a public statement that details our position on access to trial data.
I hope that Dr.Tovey’s sentiment was formally communicated to the Tribunal deliberating an appeal by the PACE investigators of a decision by the UK Information Commissioner that the trial data must be released to someone who had requested it.
I also hope that Dr. Tovey and the Cochrane recognize the implications of the PACE investigators thus far only being willing to share their data when they have authorship and therefore some control over the interpretation of their data. As Dr.Tovey notes, simply providing data does not meet the conditions for authorship:
It is also important that all authors within a review team meet the requirements of the International Committee of Medical Journal Editors (ICMJE) in relation to authorship.
These requirements mean that all authors must approve the final version of the manuscript before it is submitted. This allows the PACE investigators to control the conclusions of the systematic review so that they support the promotion of cognitive behavior and graded exercise therapy as the most evidence-supported treatments for chronic fatigue syndrome.
A favorable evaluation by the Cochrane will greatly increase the value of the PACE group’s consultations, including recommendations that disabled persons be denied benefits if they do not participate in these “best-evidence”interventions.
I’m pleased that Dr. David Tovey reiterated the Cochrane’s strong position on disclosures of conflict of interest being necessary but not sufficient to ensure the integrity of systematic reviews:
Cochrane is still fairly unusual within the journal world in that it specifies that in some cases declaration of interests is necessary but insufficient, and that there are individuals or groups of researchers who are not permitted to proceed with a given systematic review.
Yet, I’m concerned that in considering the threat of disclosed and undisclosed conflicts of interest, Dr. Tovey and the Cochrane narrowly focus on Pharma and medical device manufacturers, to the exclusion of other financial ties, such as the large disability re-insurance industry:
Within the 2014 policy it was made explicit that review authors could not be employed by pharmaceutical companies, device manufacturers or individuals that were seeking or holding a patent relevant to the intervention or a comparator product. Furthermore, in all cases, review author teams are required to have a majority of non-conflicted authors and the lead author should also be non-conflicted. The policy is available freely.
[The Cochrane apparently lacks an appreciation of the politics and conflicts of interest of the PACE trial. The trial has the unusual if not unique distinction of being a psychotherapy trial funded in part by the UK Department of Work and Pensions, which had a hand in its design. It’s no accident that the PACE investigators include paid consultants to the re-insurance industry. For more on this mess, see The Misleading Research at the Heart of Disability Cuts.
It also doesn’t help that the PACE investigators routinely fail to declare conflicts of interest. They failed to disclose their conflicts of interest to patients being recruited for the study. They failed again until they were caught in declaring no conflicts of interest in a protocol for another systematic review.
Dr. Tovey goes on to state:
Authors of primary studies should not extract data from their own study or studies. Instead, another author(s) or an editor(s) should extract these data, and check the interpretation against the study report and any available study registration details or protocol.
The Larun et al systematic review of graded exercise therapy violates this requirement. The meta-analyses forming the basis of this review is not reproducible from the published registrations, original protocols, and findings of the original studies.
Dr. Tovey is incorrect on one point:
James Coyne states that Lillebeth Larun is employed by an insurance company, but I am unclear on what basis this is determined. Undeclared conflicts of interest are a challenge for all journals, but when they are brought to our attention, they need to be verified. In any case, within Cochrane it would be a matter for the Funding Arbiters and Arbitration Panel to determine whether this was a sufficiently direct conflict to disbar her from being first author of any update.
I can’t find anywhere that I have said that Lillebeth Larun is employed by an insurance company. But I did say that she has undeclared conflicts of interest. These echo in her distorted judgments and defensive responses to criticisms of decisions made in the review that favor the PACE investigators’ vested interest.
Accepting Dr. Toby’s suggestion, I’ll be elaborating my concerns in a formal complaint to Cochrane’s Funding Arbiters and Arbitration Panel. But here is a selection of what I previously said:
Larun dismisses the risk of bias associated with the investigators not sticking to the primary outcomes in their original protocol. She suggested deviations from these outcomes were specified before analyses commenced. However, this was an unblinded trial and the investigators could inspect incoming data. In fact, they actually sent out a newsletter to participants giving testimonials about the benefits of the trial while they were still recruiting patients. Think of it: if someone with ties to the pharmaceutical industry could peek at incoming data and make changes to designate outcomes, wouldn’t that be a high risk of bias? Of course.
Laurun was responding to an excellent critique of the published review by Tom Kindlon, which you can find here.
Other serious problems with the review are hidden from the casual reader. In revising their primary outcomes specified in the original proposal, the PACE investigators had access to the publicly available data from the sister FINE trial (Weardon, 2010).
Wearden AJ, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK, Peters S, Riste L, Richardson G, Lovell K, Dunn G; Fatigue Intervention by Nurses Evaluation (FINE) trial writing group and the FINE trial group. Nurse led, home based self help treatment for patients in primary care with chronic fatigue syndrome: randomised controlled trial. BMJ. 2010 Apr 23;340:c1777. doi: 10.1136/bmj.c1777.
These data from the FINE trial clearly indicated that the existing definition of the primary outcomes in the PACE trial registration would likely not provide evidence of the efficacy of cognitive behavior or graded exercise therapy. Not surprisingly, the PACE investigators revised their scoring of primary outcomes.
Moreover, the Larun et al review misrepresents how effect sizes for the FINE trial were calculated. The review wrongly claimed that only protocol-defined and published data or outcomes were used for analysis of the Wearden 2010 study.
Robert Courtney documents in a pending comment that the review relied on an alternative unpublished set of data. As Courtney points out, the differences are not trivial.
Yet, the risk of bias table in the review for the Wearden study states:
Financial support for a meeting between Dr. Lillebeth Larun and PACE investigators
The statement of funding for the 2014 protocol indicates that Peter White financed meetings at Queen Mary University in 2013. If this were a Pharma-supported 2016 systematic review, wouldn’t Lauren have to disclose a conflict of interest for attendance at the the 2014 meeting sponsored by PACE investigators?
Are these meetings the source of the acknowledgment in the 2016 systematic review?
We would like to thank Peter White and Paul Glasziou for advice and additional information provided. We would also like to thank Kathy Fulcher, Richard Bentall, Alison Wearden, Karen Wallman and Rona Moss-Morris for providing additional information from trials in which they were involved.
The declared conflicts of interest of the PACE investigators in The Lancet paper constitute a high risk of bias. I am familiar with this issue because our article which won the Bill Silverman Award highlighted the importance of authors’ conflicts of interest being associated with exaggerated estimates of efficacy. The award to us was premised on our article having elicited a change in Cochrane policy. My co-author Lisa Bero wrote an excellent follow-up editorial for Cochrane on this topic.
This is a big deal and action is needed
Note that this 2016 systematic review has only three new studies considered that were not included in the 2004 review. So, the misrepresentations and incorrect calculation of effect sizes for two added trials– PACE and FINE – are decisive.
As it stands, the Larun et al Cochrane Review is an unreliable summary of the literature concerning exercise for “chronic fatigue syndrome.” Policymakers, clinicians, and patients should be warned. It serves the interests of politicians and re-insurance companies–and declared and undeclared interest of the PACE investigators.
I would recommend that Dr. Lillebeth Larun recuse herself from further commentary on the 2016 systematic review until complaints about her conflicts of interest and unreproducibility of the review are resolved. The Cochrane should also publish an Expression of Concern about the review, detailing the issues that have been identified here.
Stay tuned for a future blog post concerning the need to move “chronic fatigue syndrome” out of the Cochrane Common Mental Disorders group.